Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment

Larry R. Kirkland, Margaret A. Fischl, Karen T. Tashima, David Paar, Thomas Gensler, Neil M. Graham, Haitao Gao, Jacqueline R. Carranza Rosenzweig, Daniel R. McClernon, Ginger Pittman, Siegrid M. Hessenthaler, Jaime E. Hernandez

Research output: Contribution to journalArticle

62 Scopus citations

Abstract

Prison inmates with human immunodeficiency virus (HIV) infection can be difficult to treat because of the complexity and intrusiveness of many combination antiretroviral therapy regimens. NZTA4007, a 24-week open-label, single-arm clinical trial involving 108 antiretroviral therapy-naive, incarcerated, HIV-infected persons, was conducted to evaluate a compact regimen (4 tablets per day) consisting of 1 lamivudine-zidovudine (150 mg/300 mg) combination tablet (COM) and one 300-mg abacavir tablet administered twice daily under directly observed treatment conditions. In the intent-to-treat observed analysis, the plasma HIV type 1 (HIV-1) RNA level remained at ≤400 copies/mL in 85% of the patients and at <50 copies/mL in 75% of the patients. Median change from baseline was -2.41 log10 copies/mL for the HIV-1 RNA level and +111 cells/mm3 for the CD4 cell count. The overall adherence to prescribed doses was 94% for patients who remained enrolled in the study. COM-abacavir given twice daily was generally well tolerated, and adverse events prompted only 4 patients to withdraw from the study.

Original languageEnglish (US)
Pages (from-to)511-518
Number of pages8
JournalClinical Infectious Diseases
Volume34
Issue number4
DOIs
StatePublished - Feb 15 2002

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment'. Together they form a unique fingerprint.

  • Cite this

    Kirkland, L. R., Fischl, M. A., Tashima, K. T., Paar, D., Gensler, T., Graham, N. M., Gao, H., Carranza Rosenzweig, J. R., McClernon, D. R., Pittman, G., Hessenthaler, S. M., & Hernandez, J. E. (2002). Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clinical Infectious Diseases, 34(4), 511-518. https://doi.org/10.1086/338400